Richard Turkington

Real-world insights into young-onset gastroesophageal adenocarcinoma: an all-Ireland population-based cancer registry analysis.

Prognostic significance of beta-adrenergic receptor expression in oesophageal adenocarcinoma.

Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer

Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer.

Cancer-associated fibroblasts are associated with neo-adjuvant treatment response in oesophageal adenocarcinoma.

212 Research Priorities for Cancers of the Oesophagus and Stomach: Recommendations from a United Kingdom & Ireland Patient and Healthcare Professional Partnership Exercise

O55 Prospective evaluation of biomarker risk stratification using capsule sponge for surveillance of barrett’s oesophagus: results from uk real-world implementation pilots

FP33 Comparison of Barrett’s oesophagus and oesophageal adenocarcinoma patients with and without reflux symptoms: an OCCAMS cohort real-world analysis

Research priorities for cancers of the oesophagus and stomach: recommendations from a UK and Ireland patient and healthcare professional partnership exercise.

Disentangling oncogenic amplicons in esophageal adenocarcinoma

Disentangling oncogenic amplicons in esophageal adenocarcinoma.

The E3 ubiquitin ligase Itch regulates death receptor and cholesterol trafficking to affect TRAIL-mediated apoptosis.

Multi-Omic Analysis of Esophageal Adenocarcinoma Uncovers Candidate Therapeutic Targets and Cancer-Selective Posttranscriptional Regulation.

Multicentre validation of CT grey-level co-occurrence matrix features for overall survival in primary oesophageal adenocarcinoma.

REsolution of Symptoms afTer Oesophago-gastric cancer REsection delphi (RESTOREd)-standardizing the definition, investigation and management of gastrointestinal symptoms and conditions after surgery.

Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinoma.

A decade of the Oesophageal Cancer Clinical and Molecular Stratification Consortium.

SMAD4 and KCNQ3 alterations are associated with lymph node metastases in oesophageal adenocarcinoma.

An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma.

Survival outcomes in early-onset oesophageal adenocarcinoma patients: A systematic review and meta-analyses.

Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.

Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline.

Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom

Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom.

Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma

Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma.

Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.

Author Correction: Pan-cancer analysis of whole genomes.